Siegfried Reich Ph.D.
Net Worth
Last updated:
What is Siegfried Reich Ph.D. net worth?
The estimated net worth of Dr. Siegfried Reich Ph.D. is at least $10,158,181 as of 9 Feb 2022. He owns shares worth $262,082 as insider, has earned $7,587,699 from insider trading and has received compensation worth at least $2,308,400 in Turning Point Therapeutics, Inc..
What is the salary of Siegfried Reich Ph.D.?
Dr. Siegfried Reich Ph.D. salary is $577,100 per year as Executive Vice President & Chief Scientific Officer in Turning Point Therapeutics, Inc..
How old is Siegfried Reich Ph.D.?
Dr. Siegfried Reich Ph.D. is 65 years old, born in 1960.
What stocks does Siegfried Reich Ph.D. currently own?
As insider, Dr. Siegfried Reich Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Turning Point Therapeutics, Inc. (TPTX) | Executive Vice President & Chief Scientific Officer | 3,448 | $76.01 | $262,082 |
What does Turning Point Therapeutics, Inc. do?
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Siegfried Reich Ph.D. insider trading
Turning Point Therapeutics, Inc.
Dr. Siegfried Reich Ph.D. has made 4 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 397 units of TPTX stock worth $14,411 on 9 Feb 2022.
The largest trade he's ever made was exercising 35,550 units of TPTX stock on 4 Mar 2021. As of 9 Feb 2022 he still owns at least 3,448 units of TPTX stock.
Turning Point Therapeutics key executives
Turning Point Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Athena Maria Countouriotis M.D. (53) Pres, Chief Executive Officer & Director
- Dr. Siegfried Reich Ph.D. (65) Executive Vice President & Chief Scientific Officer
- Mr. Andrew John Partridge (56) Executive Vice President & Chief Commercial Officer
- Ms. Annette C. North Esq., LLB (59) Executive Vice President, Gen. Counsel & Company Sec.